Nearly two years after Takeda pulled its US marketing application for a vaccine against dengue fever, MSD has advanced a rival shot into phase 3. The international MOBILIZE-1 trial is looking at a ...
MSD will soon enter the market for drugs used to protect infants from respiratory syncytial virus (RSV) infections after getting approval from the FDA for its antibody therapy Enflonsia. The green ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback